Clinical Trial Update: Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating boron neutron capture therapy combined with cetuximab for locally recurrent head and neck cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Boron Neutron Capture Therapy (boron neutron capture therapy)
• Cetuximab (cetuximab)

Snippet

Sponsor: Boneca Corporation | Conditions: Head and Neck Cancer | Phase 1, Phase 2 | Status: TERMINATED